» Articles » PMID: 30636087

Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Augments Sphincter Bursting and Bladder Afferent Activity to Enhance Storage Function and Voiding Efficiency in Mice

Overview
Journal BJU Int
Specialty Urology
Date 2019 Jan 13
PMID 30636087
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To investigate the influence of low-dose sildenafil, a phosphodiesterase type 5 inhibitor (PDE5-I), on the function of the mouse lower urinary tract (LUT).

Materials And Methods: Adult male mice were decerebrated and arterially perfused with a carbogenated Ringer's solution to establish the decerebrate arterially perfused mouse (DAPM). To allow distinction between central neural and peripheral actions of sildenafil, experiments were conducted in both the DAPM and in a 'pithed' DAPM, which has no functional brainstem or spinal cord. The action of systemic and intrathecal sildenafil on micturition was assessed in urethane-anaesthetised mice.

Results: In the DAPM, systemic perfusion of sildenafil (30 pm) decreased the voiding threshold pressure [to a mean (sem) 84.7 (3.8)% of control] and increased bladder compliance [to a mean (sem) 140.2 (8.3)% of control, an effect replicated in the pithed DAPM]. Sildenafil was without effect on most voiding variables but significantly increased the number of bursts of the external urethral sphincter (EUS) per void in DAPM [to a mean (sem) 130.1 (6.9)% of control at 30 pm] and in urethane-anaesthetised mice [to a mean (sem) 117.5 (5.8)% of control at 14 ng/kg]. Sildenafil (10 and 30 pm) increased pelvic afferent activity during both bladder filling and the isovolumetric phase [to a mean (sem) 205.4 (30.2)% of control at 30 pm]. Intrathecal application of sildenafil (5 μL of either 150 pm or 1.5 nm) did not alter cystometry and EUS-electromyography variables in urethane-anaesthetised mice.

Conclusions: Low-dose sildenafil increases bladder compliance, increases pelvic nerve afferent activity, and augments the bursting activity of the EUS. We propose that the novel actions on afferent traffic and sphincter control may contribute to its beneficial actions to restore storage and voiding efficiency in LUT dysfunction.

Citing Articles

Advancing respiratory-cardiovascular physiology with the working heart-brainstem preparation over 25 years.

Paton J, Machado B, Moraes D, Zoccal D, Abdala A, Smith J J Physiol. 2022; 600(9):2049-2075.

PMID: 35294064 PMC: 9322470. DOI: 10.1113/JP281953.


Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder.

He W, Xiang H, Liu D, Liu J, Li M, Wang Q J Cell Mol Med. 2020; 24(22):13181-13195.

PMID: 33009887 PMC: 7701571. DOI: 10.1111/jcmm.15926.


Probabilistic, spinally-gated control of bladder pressure and autonomous micturition by Barrington's nucleus CRH neurons.

Ito H, Sales A, Fry C, Kanai A, Drake M, Pickering A Elife. 2020; 9.

PMID: 32347794 PMC: 7217699. DOI: 10.7554/eLife.56605.


The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health.

Zhao H, Kim H Curr Urol Rep. 2019; 20(10):58.

PMID: 31468204 DOI: 10.1007/s11934-019-0930-4.


Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice.

Chakrabarty B, Ito H, Ximenes M, Nishikawa N, Vahabi B, Kanai A Br J Pharmacol. 2019; 176(13):2227-2237.

PMID: 30924527 PMC: 6555867. DOI: 10.1111/bph.14669.

References
1.
Walker D, Ackland M, JAMES G, Muirhead G, Rance D, Wastall P . Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999; 29(3):297-310. DOI: 10.1080/004982599238687. View

2.
Qiu Y, Kraft P, Craig E, Liu X, Haynes-Johnson D . Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology. 2002; 59(1):145-9. DOI: 10.1016/s0090-4295(01)01471-6. View

3.
Oger S, Behr-Roussel D, Gorny D, Lebret T, Validire P, Cathelineau X . Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol. 2010; 160(5):1135-43. PMC: 2936023. DOI: 10.1111/j.1476-5381.2010.00748.x. View

4.
Liu L, Zheng S, Han P, Wei Q . Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011; 77(1):123-9. DOI: 10.1016/j.urology.2010.07.508. View

5.
Yan H, Zong H, Cui Y, Li N, Zhang Y . The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Sex Med. 2014; 11(6):1539-45. DOI: 10.1111/jsm.12499. View